Xencor Inc (NASDAQ:XNCR) shot up 7.6% on Friday . The company traded as high as $30.09 and last traded at $29.98. 681,554 shares changed hands during mid-day trading, an increase of 208% from the average session volume of 221,113 shares. The stock had previously closed at $27.85.

A number of brokerages have weighed in on XNCR. Cantor Fitzgerald reissued an “overweight” rating on shares of Xencor in a report on Friday, November 23rd. BidaskClub raised shares of Xencor from a “hold” rating to a “buy” rating in a report on Tuesday, January 1st. Nomura downgraded shares of Xencor from a “neutral” rating to a “reduce” rating and cut their price target for the company from $28.00 to $21.00 in a report on Friday, February 22nd. Zacks Investment Research raised shares of Xencor from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Thursday, December 20th. Finally, Raymond James began coverage on shares of Xencor in a report on Thursday. They issued an “outperform” rating and a $40.00 price target for the company. Two investment analysts have rated the stock with a sell rating and nine have issued a buy rating to the stock. Xencor has an average rating of “Buy” and an average target price of $41.78.

The firm has a market capitalization of $1.57 billion, a PE ratio of -22.89 and a beta of 1.40.

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in Xencor by 5.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 251,155 shares of the biopharmaceutical company’s stock worth $9,787,000 after buying an additional 12,320 shares during the period. Tower Research Capital LLC TRC acquired a new stake in Xencor during the 3rd quarter worth about $142,000. AQR Capital Management LLC raised its holdings in Xencor by 105.6% during the 3rd quarter. AQR Capital Management LLC now owns 63,061 shares of the biopharmaceutical company’s stock worth $2,457,000 after buying an additional 32,389 shares during the period. Tekla Capital Management LLC acquired a new stake in Xencor during the 4th quarter worth about $2,031,000. Finally, Artal Group S.A. raised its holdings in Xencor by 25.0% during the 3rd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $19,485,000 after buying an additional 100,000 shares during the period. Hedge funds and other institutional investors own 83.42% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Xencor (XNCR) Shares Up 7.6%” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/xencor-xncr-shares-up-7-6/2897239.html.

About Xencor (NASDAQ:XNCR)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Read More: Is the QQQ ETF safe?

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.